176 related articles for article (PubMed ID: 33378020)
21. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Jacot W; Heudel PE; Fraisse J; Gourgou S; Guiu S; Dalenc F; Pistilli B; Campone M; Levy C; Debled M; Leheurteur M; Chaix M; Lefeuvre C; Goncalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Courtinard C; Cottu P; Robain M; Mailliez A
Int J Cancer; 2019 Dec; 145(12):3359-3369. PubMed ID: 31087564
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
Trials; 2020 May; 21(1):391. PubMed ID: 32381018
[TBL] [Abstract][Full Text] [Related]
23. The safety of eribulin for the treatment of metastatic breast cancer.
Perez-Garcia JM; Cortes J
Expert Opin Drug Saf; 2019 May; 18(5):347-355. PubMed ID: 31107111
[No Abstract] [Full Text] [Related]
24. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Dell'Ova M; De Maio E; Guiu S; Roca L; Dalenc F; Durigova A; Pinguet F; Bekhtari K; Jacot W; Pouderoux S
BMC Cancer; 2015 Oct; 15():659. PubMed ID: 26449988
[TBL] [Abstract][Full Text] [Related]
25. [Treatment Out Come of Eribulin in Patients with Advanced or Metastatic Breast Cancer Who Resistant to Anthracycline and Taxane].
Tanaka N; Ogura K; Hattori A; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Naritaka Y; Hirano A
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1200-1202. PubMed ID: 29394580
[TBL] [Abstract][Full Text] [Related]
26. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
Twelves C; Cortes J; Vahdat LT; Wanders J; Akerele C; Kaufman PA
Clin Breast Cancer; 2010 Apr; 10(2):160-3. PubMed ID: 20299316
[TBL] [Abstract][Full Text] [Related]
27. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
Schwartzberg L; McIntyre K; Wilks S; Puhalla S; O'Shaughnessy J; Berrak E; He Y; Vahdat L
BMC Cancer; 2019 Jun; 19(1):578. PubMed ID: 31195996
[TBL] [Abstract][Full Text] [Related]
28. Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report.
Nettuno R; Menditto C
Oncology; 2018; 94 Suppl 1(Suppl 1):16-18. PubMed ID: 30036877
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.
Lin YJ; Kuo CN; Ko Y
Breast; 2021 Jun; 57():18-24. PubMed ID: 33706025
[TBL] [Abstract][Full Text] [Related]
30. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Manso L; Moreno Antón F; Izarzugaza Perón Y; Delgado Mingorance JI; Borrega García P; Echarri González MJ; Martínez-Jañez N; López-González A; Olier Garate C; Ballesteros García A; Chacón López-Muñíz I; Ciruelos Gil E; García-Sáenz JA; Paz-Ares L
Breast J; 2019 Mar; 25(2):219-225. PubMed ID: 30734437
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
[TBL] [Abstract][Full Text] [Related]
32. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
Kikuchi Y; Uchida Y; Shirakawa K; Kanauchi H; Niwa T; Nishioka K; Tada K; Hashimoto M; Yasuda H; Sugiura R; Kawabata H; Seto Y; Ogawa T
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e231-e237. PubMed ID: 29498210
[TBL] [Abstract][Full Text] [Related]
34. Eribulin mesylate.
Jain S; Vahdat LT
Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
[TBL] [Abstract][Full Text] [Related]
35. Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life.
Sari M; Saip P
Indian J Cancer; 2020; 57(1):55-61. PubMed ID: 31929236
[TBL] [Abstract][Full Text] [Related]
36. Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund.
Ramaswami R; O'Cathail SM; Brindley JH; Silcocks P; Mahmoud S; Palmieri C
Future Oncol; 2014 Feb; 10(3):363-76. PubMed ID: 24367990
[TBL] [Abstract][Full Text] [Related]
37. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.
Poletti P; Ghilardi V; Livraghi L; Milesi L; Rota Caremoli E; Tondini C
Future Oncol; 2014 Feb; 10(2):233-9. PubMed ID: 24490609
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.
O'Shaughnessy J; Cortes J; Twelves C; Goldstein LJ; Alexis K; Xie R; Barrios C; Ueno T
Sci Rep; 2020 Jul; 10(1):11203. PubMed ID: 32641747
[TBL] [Abstract][Full Text] [Related]
39. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies.
O'Shaughnessy J; McIntyre K; Schwartzberg L; Wilks S; Puhalla S; Berrak E; Song J; Vahdat L
Springerplus; 2015; 4():532. PubMed ID: 26413438
[TBL] [Abstract][Full Text] [Related]
40. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
